MARLBOROUGH, Mass., Feb. 5, 2025
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational basis and 19.5 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted EPS of $0.70 for the period, compared to $0.55 a year ago.
For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6 percent on a reported basis, 18.5 percent on an operational basis and 16.4 percent on an organic basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago, and delivered full year adjusted EPS of $2.51, compared to $2.05 a year ago.
"2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE™ Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world."
Fourth quarter financial results and recent developments:
- Operational net sales growth excludes the impact of foreign currency fluctuations.
- Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
- Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union Medical Device Regulation (EU MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.
Fourth quarter net sales by business and region:
| Business |
2024 |
2023 |
| Endoscopy |
$690 million |
$645 million |
| Urology |
$630 million |
$527 million |
| Neuromodulation |
$299 million |
$269 million |
| MedSurg |
$1,619 million |
$1,441 million |
| Cardiology |
$2,297 million |
$1,751 million |
| Peripheral Interventions |
$645 million |
$533 million |
| Cardiovascular |
$2,942 million |
$2,285 million |
Guidance for Full Year and First Quarter 2025
The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and approximately 10 to 12 percent on an organic basis.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements. Readers are cautioned not to place undue reliance on these statements.
Contact:
Media: Chanel Hastings
Investors: Jonathan Monson
Phone: 508-382-0288 (office)
Email: [email protected]
BOSTON SCIENTIFIC CORPORATION
